Your Mounjaro pen has a cherry-coloured label — here's what that tells you

Cherry Mounjaro is the 5 mg strength of tirzepatide, colour-coded to distinguish it from the 2.5 mg (grey), 7.5 mg, 10 mg, 12.5 mg and 15 mg pens.
Tirzepatide activates both GIP and GLP-1 receptors, the only licensed dual-agonist for weight management in the UK.
Moving from 2.5 mg to 5 mg is a prescriber decision, typically made after four weeks on the starter dose, based on how well the first pen was tolerated.
All strengths require refrigerated storage between 2°C and 8°C; the exact room-temperature window for any pen is given in the Patient Information Leaflet.

Cherry Mounjaro refers to the 5 mg strength of tirzepatide, identifiable by the cherry-red colour coding on its KwikPen label and packaging. Each Mounjaro strength has its own distinct colour so that patients and clinicians can distinguish doses at a glance — cherry is the 5 mg pen, the first step up from the 2.5 mg starter dose. Like all Mounjaro strengths, this is a prescription-only medicine that can only be supplied following a clinical assessment by a qualified prescriber. You'll find the full picture of how the dose schedule works, and what the colours mean at every stage, below.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The colour-coding system, what cherry means in practice, and when a prescriber moves you to 5 mg

You've opened the box and spotted a cherry-red label, now what?

Picture this: your Mounjaro delivery arrives, you open the plain outer packaging, and the pen label is a deep cherry red. If you were expecting a grey label from your starter pen, that pause is understandable. The colour change is intentional. Eli Lilly colour-codes every Mounjaro strength so that picking up the wrong pen at the back of the fridge door is less likely, a small but meaningful safety feature for anyone who has more than one strength at home during a transition.

Cherry is the assigned colour for 5 mg tirzepatide. The 2.5 mg pen is grey, and the higher doses each carry their own distinct colour. The full Mounjaro overview covers the complete range of six licensed UK strengths. The colour system runs across both the KwikPen cap and the label, so it is visible even when the pen is stored upright. Confirming your strength before each weekly injection is a good habit regardless, cross-check the number printed on the label alongside the colour.

If your cherry pen arrived and you were not expecting it, the right move is to contact your prescriber before injecting. At nume, our support team is available seven days a week for exactly this kind of query.

Why 2.5 mg comes first and 5 mg follows, the reasoning behind tirzepatide's dose steps

The 2.5 mg starting pen exists for one reason: to help your system adjust. Tirzepatide slows gastric emptying and reduces appetite through two receptor pathways (GIP and GLP-1) and that activity can cause nausea or digestive discomfort in the first weeks, especially at higher doses. Starting low gives those effects the best chance of staying manageable. The NHS tirzepatide page describes this tolerability rationale clearly for patients.

After roughly four weeks, a prescriber reviews how the first pen was tolerated. If things have settled, the next step is 5 mg, the cherry pen. This is not a sudden jump in clinical effect; it is a measured increase intended to build on the initial adjustment. Many people find the transition straightforward. Others need a little longer at 2.5 mg, and a good prescriber will say so rather than push the schedule for its own sake.

The cherry 5 mg pen is also a KwikPen containing four weekly doses, used the same way as the starter: subcutaneous injection into the abdomen, thigh or upper arm, rotating sites each week. Exact technique is covered in the Patient Information Leaflet included with your pen. Questions about whether your dose is working well are best brought to your prescriber rather than resolved by adjusting the schedule yourself.

Side effects at the 5 mg stage and when to seek help

The side-effect profile at 5 mg is broadly the same GI-led pattern documented across the SURMOUNT clinical programme and summarised on the NHS medicines page for tirzepatide: nausea, loose stools, constipation, indigestion and reduced appetite. These are most noticeable in the days after a new dose, and they tend to ease as the weeks pass.

A small number of people experience more than mild discomfort. Severe, persistent stomach pain that radiates toward the back (with or without vomiting) needs urgent medical attention; this can be a sign of pancreatitis, and the MHRA has specifically highlighted it as a serious but infrequent risk with GLP-1 medicines. Do not wait it out. Call 111 or go to A&E.

Other symptoms that should not be ignored include signs of a serious allergic reaction, significant dizziness, or anything that simply feels wrong and persists. Our guide to chest pain and Mounjaro and the page on blurred vision while on tirzepatide cover two questions our prescribers hear regularly, and if you are specifically concerned about cardiac symptoms our detailed resource on chest pains and Mounjaro explains what to watch for and when to act. Patients and carers can also report suspected side effects directly through the MHRA Yellow Card scheme.

Storage, travel and staying on track with your cherry pen

Every Mounjaro pen, cherry or otherwise, is stored in the fridge at 2°C to 8°C. The pen can sit at room temperature for a limited period if you are away from home, but the exact window is stated in the Patient Information Leaflet rather than here, the leaflet is the authoritative source and varies slightly between batches. Keep the pen in its original packaging away from light.

If you are planning to travel with your cherry pen, the rules around carrying prescription medicines on flights are worth reading before you pack. The dedicated page on taking Mounjaro on a plane covers what documentation helps and how to keep the pen cool in transit.

For context on what private treatment involves cost-wise, the Mounjaro cost page sets out how pricing works across dose stages, including what a legitimate private service should include beyond the pen itself. At nume, one price covers the clinical review, the prescription and tracked next-working-day delivery, no extras added at checkout.

Ready to discuss whether tirzepatide is right for you? Start your free consultation and a GPhC-registered prescriber will review your answers the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions